Morgan Stanley began coverage on shares of Prevail Therapeutics (NASDAQ:PRVL) in a report issued on Monday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $20.00 price objective on the stock.
Several other research analysts also recently commented on PRVL. Wedbush set a $19.00 target price on Symantec and gave the stock a hold rating in a research note on Monday. Bank of America set a $68.00 target price on Inphi and gave the stock a buy rating in a research note on Monday. Finally, Cowen reissued a buy rating on shares of Avrobio in a research note on Monday.
PRVL stock opened at $12.10 on Monday. Prevail Therapeutics has a 52 week low of $9.83 and a 52 week high of $16.90.
In other Prevail Therapeutics news, Director Carl L. Gordon bought 882,352 shares of the stock in a transaction on Monday, June 24th. The stock was purchased at an average price of $17.00 per share, with a total value of $14,999,984.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Prevail Therapeutics Company Profile
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Further Reading: What is Blockchain?
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.